 Bapineuzumab was discontinued after failing in Phase III clinical trial

Solanezumab, an anti-aβ MAB, targets the N-terminus of Aβ.In Phase I and Phase II of clinical trials, Solanezumab treatment resulted in cerebrospinal fluid elevation of Aβ, thereby showing a reduced concentration of Aβ plaques.Additionally, there are no associated adverse side effects.